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Background: Levofloxacin is used in adult patients with cystic fibrosis but its pharmacokinetics is not well characterized in this population.
Patients with cystic fibrosis use calcium routinely to prevent osteoporosis. A slower intestinal transit time is common in cystic fibrosis
implying that the standard 2-h spacing of minerals and levofloxacin to prevent a chelation interaction may be insufficient. The objectives of
this study were to characterize the steady state pharmacokinetics of oral levofloxacin 750mg with and without 2-h spaced calcium carbonate
in patients with cystic fibrosis compared to matched healthy volunteers.
Methods: In an open-label, randomized, cross-over study of five patients with cystic fibrosis and five age, sex, race, and serum creatinine
matched healthy volunteers received 750mg of oral levofloxacin alone daily for 5 days and the same dose of levofloxacin with 2-h spaced
calcium carbonate supplementation 500mg po thrice daily with meals in random sequence. Blood was collected for plasma assay of
levofloxacin pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, and 24h after the fifth levofloxacin dose.
Results: There was no significant interaction in healthy volunteers, however, when cystic fibrosis patients were given levofloxacin with 2-
h spaced calcium, the maximum plasma concentration (Cmax) decreased by 19% and time to Cmax increased by 37% ( p <0.05). This
difference in peak concentrations resulted in a lack of bioequivalence (Cmax geometric mean ratio 81.6%, 90% confidence intervals: 71.8%,
91.4%) even when levofloxacin and calcium supplements were spaced by the standard 2h administration instruction in patients with cystic
fibrosis.
Conclusions: These results indicate that multivalent cations such as calcium should be maximally separated from oral levofloxacin
administration in adult patients with cystic fibrosis to prevent this drug interaction, thereby better optimizing antibiotic efficacy and
decreasing the potential for resistance development.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Levofloxacin is a fluoroquinolone antimicrobial agent
available as both an intravenous and a near 100%
bioavailable oral formulation [1]. Levofloxacin has a broad
spectrum of activity, including penicillin-resistant Strepto-
coccus pneumoniae and Pseudomonas aeruginosa and has
been approved for the management of a variety of systemic
infections [1]. The fluoroquinolones namely levofloxacin1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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E-mail address: apai@salud.unm.edu (M.P. Pai).and ciprofloxacin are the most common oral antibacterial
agents currently used to manage systemic infections caused
by Pseudomonas aeruginosa [2]. However, ciprofloxacin
must be dosed twice to three times a day as compared to
once daily with levofloxacin to adequately manage these
infections [2].
P. aeruginosa commonly colonizes the respiratory tract
of patients with cystic fibrosis and is associated with a rapid
decline in respiratory function of these patients [3]. The
availability of potent antibiotics active against P. aeruginosa
has played a major role in improving the clinical outcomes
of patients with cystic fibrosis [4]. These patients are often
admitted during an acute pulmonary exacerbation to receive
a 2–3 week intravenous antipseudomonal antibiotic com-5 (2006) 153 – 157ed by Elsevier B.V. All rights reserved.
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cations like levofloxacin has allowed for the increased
utilization of both initial outpatient management strategies
for acute pulmonary exacerbations or as oral follow-up and
earlier discharge for those admitted and initially treated with
intravenous antibiotics [5].
Fluoroquinolones are known to interact with multivalent
cations such as aluminum, magnesium, iron, and calcium by
forming non-absorbable ion-quinolone chelates in the
stomach and small intestine [6]. Depending on the closeness
of administration, the extent of absorption or area under the
curve (AUC) of levofloxacin can be decreased by up to 40%
with aluminum and magnesium [7]. As a result, the
manufacturer of levofloxacin recommends that the admin-
istration of supplements containing aluminum, zinc, mag-
nesium, or iron be separated by at least 2h [8]. No specific
recommendation on the timing of administration of levo-
floxacin and calcium containing supplements is addressed in
the product labeling [8]. In addition there are no published
studies evaluating the pharmacokinetic profile of levoflox-
acin in patients with cystic fibrosis.
Cystic fibrosis is associated with numerous pathological
changes that can alter the disposition of drugs [9]. Fat
malabsorption is common in cystic fibrosis and can increase
the gastric emptying and intestinal transit times, which can
affect the rate of drug absorption [10]. Although fat
malabsorption can be rectified by the administration of
exogenous pancreatic enzymes, the mean gastric emptying
and small intestinal transit times may be twice as long in
patients with cystic fibrosis compared to healthy subjects
[10,11]. Consequently, a 2-h spacing recommendation of
levofloxacin with cations such as iron, aluminum or even
calcium may not be sufficient to prevent a chelation
interaction in these patients. Adult patients with cystic
fibrosis are frequently prescribed calcium carbonate to
prevent osteoporosis and may be at risk for this interaction
[12]. The current study was performed to assess the
interaction between levofloxacin and 2-h spaced calcium
carbonate in patients with cystic fibrosis compared to
matched controls.2. Methods
This randomized, cross-over study included five adult
subjects with cystic fibrosis and five sex, age, race, weight,
and serum creatinine matched healthy volunteers. The
University of New Mexico Human Research Review
Committee approved this study and subjects provided
written informed consent prior to any study related activities
taking place. Subjects were eligible for inclusion based on
the following criteria: [1] males and females, 18 to 45 years
of age; [2] non-smoking volunteers; [3] within 30% of their
ideal body weight for height and sex; and [4] female
subjects of childbearing potential either surgically sterilized,
using an effective method of contraception or agree toabstain from sex from time of pre-study screening, during
entire study period and 1 week following the study period.
In addition subjects were excluded if any of the following
criteria were met: [1] a clinically significant chronic medical
condition requiring the use of pharmacological or non-
pharmacological management (healthy volunteers only); [2]
a history of adverse reactions to fluoroquinolones or
calcium carbonate; [3] donated blood or participated in
another study within 60 days of this study; [4] pregnant or
breastfeeding females; [5] unwilling to abstain from all
prescription medications, non-prescription medications,
herbals, or vitamins for 7 days prior to study (healthy
volunteers only); [6] unwilling to abstain from alcohol,
cigarette smoking, and caffeine intake during study period
(21 days); [7] clinically significant abnormal physical
examination defined as a physical finding requiring further
work-up or management with a pharmacological or non-
pharmacological intervention (healthy volunteers only); [8]
any acute illness including a respiratory exacerbation,
pancreatitis, or biliary stenosis within 30 days of screening;
[9] an abnormal electrocardiogram (QTc>450msec); [10]
an abnormal laboratory result (complete blood count, serum
chemistry, transaminases, and total bilirubin); [11] calculat-
ed creatinine clearance <50mL/min; [12] a forced expira-
tory volume in 1s (FEV1) <30% of predicted or enrolled in
a recipient lung transplant list (CF subjects only); [3] FEV1
instability defined as >10% decrease in FEV1 between
screening and randomization; [14] unable to tolerate
venipuncture and multiple blood samplings. Measurement
of FEV1 was performed by trained personnel in an on site
respiratory therapy testing lab.
All enrollees were randomized to receive oral levoflox-
acin (Levaquin\, Ortho-McNeil) 750mg once daily and
calcium carbonate (OsCal\, GlaxoSmithKline Consumer)
500mg thrice daily with meals, or levofloxacin 750mg once
daily alone for 5 days with a subsequent cross-over to the
alternative regimen after a 7-day washout phase. Study
subjects were instructed to self-administer their dose of
levofloxacin with 12 ounces of water, 2h after their
breakfast and, if they were taking calcium, 2h prior to their
lunch time doses of calcium carbonate. Study enrollees
received standardized caffeine free meals (35–40kcal/kg/
day) consisting of 50% carbohydrate, 20% protein, and 30%
fat for breakfast, lunch and dinner for each of the 5 days
during the pharmacokinetic phase of the study. Subjects
received the prepackaged meals through the clinical
research center bionutrition kitchen. The meals included
the recommended daily allowances of vitamins and miner-
als, and did not contain any mineral-enriched (ex. calcium,
iron, etc.) foods or drinks. Compliance was assessed by
inspection of study medication and food diaries, pill counts,
and subject interviews.
Subjects were admitted at 0600h to the University of
New Mexico Clinical Research Center on the fifth day of
levofloxacin dosing for a 24-h stay. Blood samples were
collected in tubes containing heparin (Vacutainers, Becton-
Table 2
Plasma levofloxacin (Levo) pharmacokinetic parameters with and without
2-h spaced calcium carbonate (CaCO3) in patients with cystic fibrosis and
healthy volunteers
Pharmacokinetic
parameters
Cystic fibrosis patients Healthy volunteers
Levo Levo+CaCO3 Levo Levo+CaCO3
Cmax (mg/L) 10.8T1.3
a 8.8T1.6 9.7T1.6 8.8T0.8
tmax (h) 1.9T0.6
b 2.6T0.9 1.8T1.4 2.4T1.3
AUC0– 24 (mg h/L) 90T21 87T19 83T12 96T23
CL/F (L/h) 8.7T1.8 9.0T2.0 9.2T1.5 8.2T2.0
Vd/F (L/kg) 1.03T0.27 1.41T0.14 1.16T0.16 1.27T0.19
t1/2 (h) 6.8T1.0 6.9T1.7 7.1T1.8 8.0T2.0
a p <0.05 compared to all three groups.
b p <0.05 compared to Levo+CaCO3 group only.
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8, 12, and 24h after the dose was administered. Calcium
carbonate dosing continued throughout the 24h of sampling
as it had during the other study days. Blood samples were
centrifuged and plasma was stored at 70 -C until analysis
and then shipped frozen with a sufficient amount of dry ice
within 12 months of collection. Plasma sample analyses
were conducted using a previously described validated high
performance liquid chromatography assay (Emprexe Ana-
lytical, LLC, Buffalo, NY) [13]. The overall precision
(percent coefficient of variation) and accuracy (percent
analytical recovery) of the levofloxacin assay were 1.37%
and 99%, respectively. Pharmacokinetic analysis of plasma
levofloxacin concentration versus time data was conducted
by non-compartmental analysis using WinNonLin Profes-
sional version 4.1 software package (Pharsight Corporation,
Mountain View, California). The effect of 2-h spaced
calcium on bioequivalence was determined to be absent if
the 90% confidence intervals (CI) were within the limits of
80% to 125% for the geometric mean ratios for the area
under the plasma concentration– time curve for 24h
(AUC0–24) or the peak plasma concentration (Cmax) [14].
Repeated measure ANOVA with time as the repeated factor
was used as the overall analysis for the comparison of
pharmacokinetic parameters. Post hoc comparisons of these
parameters were performed using Student’s paired t-test
following Fisher’s least significant difference method.
Statistical analyses were performed using SPPS for Win-
dows version 10.0 (SPSS Inc., Chicago, Illinois). Fisher’s
exact test was used to compare categorical demographic
variables. Differences between groups were considered
significant at a p-value<0.05.3. Results
Thirteen subjects (five patients with cystic fibrosis) gave
written informed consent, and 10 subjects completed the
study (five patients with cystic fibrosis and five healthy
volunteers). Three subjects (all healthy volunteers) were
withdrawn from the study because of an inability to attain
intravenous access in two cases and dizziness related to
levofloxacin use in one case. There were no serious adverseTable 1
Demographic characteristics of patients with cystic fibrosis and healthy
volunteers
Characteristic Cystic fibrosis
patients
Healthy
volunteers
p-value
Number 5 5 1.0
Sex 3 female 3 female
2 male 2 male 1.0
Caucasian race 100% 100% 1.0
Age (years) 30T12 31T8 0.43
Weight (kg) 61.5T7.6 67.8T7.1 0.58
Serum creatinine (mg/dL) 0.8T0.2 0.7T0.2 0.61events during the study, and 100% compliance was
documented with study related procedures. The demograph-
ic characteristics of the enrollees are summarized in Table 1.
There were no statistically significant differences between
groups in regards to age, sex, serum creatinine and weight,
and all subjects were of Caucasian race.
The pharmacokinetic data are summarized in Table 2.
The steady-state levofloxacin Cmax was a mean 10% higher
in patients with cystic fibrosis compared to healthy
volunteers when levofloxacin was administered alone
( p <0.05). In contrast, the levofloxacin Cmax decreased by
a mean of 19% in cystic fibrosis patients when administered
in conjunction with the 2-h spaced calcium carbonate. This
reduction in Cmax was also associated with a 37% increase
in the tmax ( p <0.05). The AUC0–24 for levofloxacin was
similar between the two groups and was not altered by the
2-h spaced calcium carbonate. When tested for bioequiva-
lence the ratio of the geometric means and 90% CI between
the control and test arms demonstrated a lack of bioequi-
valence in terms of Cmax, 81.6% [71.8%, 91.4%] but not
AUC0–24, 96.8% [87.4%, 106.2%] in cystic fibrosis
patients. In contrast, bioequivalence was demonstrated for
both pharmacokinetic parameters in the healthy volunteers.
The ratio of the geometric means and 90% CI between the
control and test arms for Cmax and AUC0–24 were 93.5%
[80.3%, 106.7%] and 114.3% [103.6%, 125%] in the
healthy volunteers, respectively.4. Discussion
The availability of potent antimicrobials and anti-
inflammatory agents has contributed to an increase in the
median age of survival of patients with cystic fibrosis from
14 years in 1969 to 32 years in 2000 [15]. However, this
emerging population of adult patients with cystic fibrosis
have far more complications such as osteoporosis. Conse-
quently, these patients often receive 1000–1500mg of
calcium supplementation per day as a preventative measure
against osteoporosis [12]. Fluoroquinolones are known to
interact with multivalent cations such as aluminum, mag-
nesium, iron, zinc and calcium by forming non-absorbable
M.P. Pai et al. / Journal of Cystic Fibrosis 5 (2006) 153–157156ion-quinolone chelates in the stomach and small intestine
[6]. The degree of this potential interaction has not been
studied in adult patients with cystic fibrosis.
In addition, the steady-state pharmacokinetic profile of
daily oral 750mg levofloxacin has not previously been
characterized in adult patients with cystic fibrosis. The
current study demonstrated that the steady-state Cmax of
levofloxacin appears to be statistically higher to those noted
in matched healthy volunteers. Previous studies evaluating
the chelation interaction of levofloxacin and cations
included concomitant administration of agents as a single
dose in healthy volunteers. The concurrent administration of
calcium significantly reduced the Cmax of levofloxacin by
22% in a healthy volunteer trial but not its AUC0–24 [7].
Although the amount of change in Cmax caused by calcium
was about the same between that study and the current one,
the interaction noted in the current study still existed when
the two were administered 2h apart for cystic fibrosis
patients.
The inter-relationship of pharmacokinetic and pharma-
codynamic parameters such as the Cmax :MIC ratio is
considered to be an important predictor of clinical outcome
with the clinical use of fluoroquinolones such as levoflox-
acin. In an often quoted example of this that used
levofloxacin specifically, achieving a Cmax :MIC ratio
>12.2 provided bacteriologic cure rates that were 99%
[16]. The development of fluoroquinolone resistant P.
aeruginosa is also an important variable to consider when
optimizing the use of these agents in patients with cystic
fibrosis. A novel in vitro test of fluoroquinolone activity
known as the mutation prevention concentration (MPC)
provides a measure of the concentration that prevents the
growth of the next-step mutant of a bacterial strain [17]. The
MPC provides a threshold value to target plasma concen-
trations in order to prevent the selection of resistance during
therapy. This mutant selective window is thought to be the
period of time that the concentrations fall between the MPC
and MIC. If the levofloxacin tmax were extended and the
levofloxacin Cmax reduced, the net effect would be an
increase in the mutant selective window. These effects on
tmax and Cmax were noted in this study among cystic fibrosis
patients receiving calcium and levofloxacin and so would
theoretically increase their probability of acquiring resis-
tance. Although, the concept of MPC has not been validated
clinically the available data suggest that a Cmax :MIC ratio
of at least 10 for ciprofloxacin and levofloxacin may
decrease the probability of resistance development [2].
Consequently, use of calcium carbonate that is inadequately
spaced with levofloxacin can reduce the Cmax of levoflox-
acin and impact the outcomes of patients with cystic fibrosis
receiving outpatient treatment for respiratory exacerbations.
Optimizing the Cmax :MIC ratio of levofloxacin in patients
with cystic fibrosis should improve efficacy and decrease
the propensity of resistance development.
More importantly, other cations such as aluminum, iron,
and magnesium may have greater impact on the absorptionof levofloxacin given that these cations historically have
had a higher chelation potential than calcium [7]. In
addition, the use of ciprofloxacin is likely to be higher
than levofloxacin for pulmonary exacerbations in patients
with cystic fibrosis given the historically larger number of
studies conducted with ciprofloxacin in this group [18].
Data suggest that current ciprofloxacin dosing regimens
may be inadequate and that a thrice-daily regimen is
probably necessary during outpatient use in these patients
[19]. Although the current study did not assess ciproflox-
acin, it is likely that the potential interaction between
ciprofloxacin and calcium carbonate may be greater given
its more frequent administration. Consequently, clinicians
should consider maximizing the separation of orally
administered levofloxacin and ciprofloxacin with multiva-
lent cations in adult patients with cystic fibrosis so as to
better assure optimal clinical and bacteriologic outcomes in
their patients.5. Conclusions
The steady state pharmacokinetic profile of levofloxacin
750mg administered once daily was similar in patients with
cystic fibrosis compared to matched healthy volunteers.
However, levofloxacin does not maintain bioequivalence
based on Cmax in patients with cystic fibrosis when
administered with 2-h spaced calcium carbonate. Maximiz-
ing the separation of levofloxacin and multivalent cations in
adult patients should be considered to prevent this drug
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